Identifying Potential Predictors of High-Quality Oral Anticoagulation Assessed by Time in Therapeutic International Normalized Ratio Range: A Prospective, Long-Term, Single-Center, Observational Study

Clinical Therapeutics

Volumn 34, Issue 7, 2012, Pages 1511-1520

  Costa, Gustavo Lamego de Barros ^a   Lamego, Rosana Morais ^b   Colosimo, Enrico A ^b   Valacio, Reginaldo Aparecido ^a   Moreira, Maria da Consolação Vieira ^b  

^a Odilon Behrens Hospital   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Anticoagulation; Quality of health care; Time in therapeutic range; Warfarin

Indexed keywords

ALCOHOL; VITAMIN K GROUP; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CAREGIVER; COGNITION; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FAMILY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL NORMALIZED RATIO; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SOCIAL SUPPORT; TIME FACTORS; VITAMIN K; YOUNG ADULT;

EID: 84863825905     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.06.002     Document Type: Article

References (54)

1. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(Suppl):160S-198S.
2. Connolly S.J., Pogue J., Eikelboom J., et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118:2029-2037.
3. Jones M., McEwan P., Morgan C.L., et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with nonvalvar atrial fibrillation: a record linkage study in a large British population. Heart 2005, 91:472-477.
4. Veeger N.J., Piersma-Wichers M., Tijssen J.G., et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005, 128:513-519.
5. White R.H., Gruber M., Feyzi J., et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Results From SPORTIF III and V. Arch Intern Med 2007, 167:239-245.
6. van Walraven C., Jennings A., Oake N., et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006, 129:1155-1166.
7. Shah S.V., Gage B.F. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011, 123:2562-2570.
8. Ma T.K., Yan B.P., Lam Y.Y. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice?. A review of clinical data. Pharmacol Ther 2011, 129:185-194.
9. Douketis J.D. Dabigatran as anticoagulant therapy for atrial fibrillation. Pol Arch Med Wewn 2011, 121:73-80.
10. Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis 2008, 25:61-66.
11. Phillips K., Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert Rev Cardiovasc Ther 2008, 6:57-70.
12. Wilson S.J.A., Wells P.S., Kovacs M.J., et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 2003, 169:293-298.
13. Nichol M.B., Knight T.K., Dow T., et al. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. Ann Pharmacother 2008, 42:62-70.
14. Garcia-Alamino J.M., Ward A.M., Alonso-Coello P., et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2010, (4). CD003839.
15. Demirkan K., Stephens M.A., Newman K.P., Self T.H. Response to warfarin and other oral anticoagulants: effects of diseases states. South Med J 2000, 93:448-454.
16. Franco V., Polanczyk C.A., Clausell N., Rohde L.E. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 2004, 116:651-656.
17. Khan T., Wynne H., Wood P., et al. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 2004, 124:348-354.
18. Davis N.J., Billett H.H., Cohen H.W., Arnsten J.H. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother 2005, 39:632-636.
19. Palareti G., Legnani C., Guazzaloca G., et al. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol 2005, 129:72-78.
20. Kimmel S.E., Chen Z., Price M., et al. The influence of patient adherence on anticoagulation control with warfarin. Results From the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med 2007, 167:229-235.
21. Rose A.J., Ozonoff A., Henault L.E., Hylek E.M. Warfarin for atrial fibrillation in community-based practice. J Thromb Haemost 2008, 6:1647-1654.
22. Rose A.J., Hylek E.M., Ozonoff A., et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010, 8:2182-2191.
23. Witt D.M., Delate T., Clark N.P., et al. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost 2010, 8:744-749.
24. Hylek E.M., Heiman H., Skates S.J., et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998, 279:657-662.
25. Wittkowsky A.K., Devine E.B. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 2004, 24:1311-1316.
26. Procidano M.E., Heller K. Measures of perceived social support from friends and from family: three validation studies. Am J Community Psychol 1983, 11:1-24.
27. Zimet G.D., Dahlem N.W., Zimet S.G., Farley G.K. The Multidimensional Scale of Perceived Social Support. J Pers Assess 1988, 52:30-41.
28. Brody D., Hahn S.R., Spitzer R.L., et al. Identifying patients with depression in the primary care setting: A more efficient method. Arch Intern Med 1998, 158:2469-2475.
29. Folstein M.F., Folstein S.E., McHugh P.R. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975, 12:189-198.
30. Almeida O.P. The Mini-Mental State Examination and the Diagnosis of Dementia in Brazil. Arq Neuropsiquiatr 1998, 56:605-612.
31. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of self-reported measure of medication adherence. Med Care 1986, 24:67-74.
32. Edelberg H.K., Shallenberger E., Wei J.Y. Medication management capacity in highly functioning community-living older adults: detection of early deficits. J Am Geriatr Soc 1999, 47:592-596.
33. Couris R.R., Tataronis G.R., Booth S.L., et al. Development of a self-assessment instrument to determine daily intake and variability of dietary vitamin K. J Am Coll Nutr 2000, 19:801-806.
34. Booth S.L., Sokoll L.J., O'Brien M.E., et al. Assessment of dietary phylloquinone intake and vitamin K status in postmenopausal women. Eur J Clin Nutr 1995, 49:832-841.
35. Presse N., Payette H., Shatenstein B., et al. A minimum of six days of diet recording is needed to assess usual vitamin K intake among older adults. J Nutr 2011, 141:341-346.
36. USDA National Nutrient Database for Standard Reference, Release 20 Agriculture USDo, Accessed March 3, 2007. http://www.ars.usda.gov/ba/bhnrc/ndl.
37. Damon M., Zhang N., Haytowitz D., Booth S. Phylloquinone (vitamin K1) content of vegetables. J Food Compost Anal 2005, 18:751-758.
38. Klack K., Carvalho J.F. Vitamin K: metabolism, sources and interaction with the anticoagulant warfarin. Rev Bras Reumatol 2006, 46:398-406.
39. Baglin T.D., Keeling D.M., Watson H.G. Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol 2006, 132:277-285. British Committee for Standards in Haematology.
40. Rosendaal F.R., Cannegieter S.C., van der Meer F.J.M., Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993, 69:236-239.
41. Riffenburgh R.H. Statistics in Medicine 2006, Elsevier Academic Press, New York, NY.
42. Connock M., Stevens C., Fry-Smith A., et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007, 11:iii-iv. ix-66.
43. Kuijer P.M., Hutten B.A., Prins M.H., Büller H.R. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999, 159:457-460.
44. Shireman T.I., Mahnken J.D., Howard P.A., et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006, 130:1390-1396.
45. Uchino B.N. Social support and health: a review of physiological processes potentially underlying links to disease outcomes. J Behav Med 2006, 29:377-387.
46. Gallant M.P. The influence of social support on chronic illness self-management: a review and directions for research. Health Educ Behav 2003, 30:170-195.
47. Dôres S.M.C., Booth S.L., Martini L.A., et al. Relationship between diet and anticoagulant response to warfarin. A factor analysis. Eur J Nutr 2007, 46:147-154.
48. Sconce E., Avery P., Wynne H., Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007, 109:2419-2423.
49. Rombouts E.K., Rosendaal F.R., Van Der Meer F.J. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 2007, 5:2043-2048.
50. Rosove M., Grody W.W. Should we be applying warfarin pharmacogenetics to clinical practice?. No, not now. Ann Intern Med 2009, 151:270-273.
51. Johnson B.T., Scott-Sheldon L.A., Carey M.P. Meta-synthesis of health behavior change meta-analyses. Am J Public Health 2010, 100:2193-2198.
52. Bertholet N., Horton N.J., Saitz R. Improvements in readiness to change and drinking in primary care patients with unhealthy alcohol use: a prospective study. BMC Public Health 2009, 9:101.
53. Spahn J.M., Reeves R.S., Keim K.S., et al. State of the evidence regarding behavior change theories and strategies in nutrition counseling to facilitate health and food behavior change. J Am Diet Assoc 2010, 110:879-891.
54. Camm A.J., Kirchhof P., et al. Guidelines for the management of atrial fibrillation. Eur Heart J 2010, 31:2369-2429. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).